SREBF2 and metabolic dysfunction-associated steatotic liver disease: Yang J. et al. 2023 [52] showed that curcumin was able to protect HFD-induced MASLD by inhibiting both intestinal and hepatic NPC1L1 expression through the down-regulation of SREBP-2/hepatocyte nuclear factor-1 alpha (HNF1α) pathway, thus reducing intestinal cholesterol absorption and hepatic cholesterol accumulation improving liver steatosis and providing evidence for curcumin as a potential nutritional therapy in patients with MASLD [52].